Your browser doesn't support javascript.
loading
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.
Felip, Isidre; Moiola, Cristian Pablo; Megino-Luque, Cristina; Lopez-Gil, Carlos; Cabrera, Silvia; Solé-Sánchez, Sonia; Muñoz-Guardiola, Pau; Megias-Roda, Elisabet; Pérez-Montoyo, Héctor; Alfon, José; Yeste-Velasco, Marc; Santacana, María; Dolcet, Xavier; Reques, Armando; Oaknin, Ana; Rodríguez-Freixinos, Victor; Lizcano, José Miguel; Domènech, Carles; Gil-Moreno, Antonio; Matias-Guiu, Xavier; Colas, Eva; Eritja, Nuria.
Afiliação
  • Felip I; Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, Lleida, Spain.
  • Moiola CP; Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, Lleida, Spain; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, CIBERONC, B
  • Megino-Luque C; Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, Lleida, Spain.
  • Lopez-Gil C; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.
  • Cabrera S; Gynecological Oncology Department, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain.
  • Solé-Sánchez S; Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona, Spain.
  • Muñoz-Guardiola P; Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona, Spain; Protein Kinases and Signal Transduction Laboratory, Institut de Neurociències and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.
  • Megias-Roda E; Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona, Spain; Protein Kinases and Signal Transduction Laboratory, Institut de Neurociències and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.
  • Pérez-Montoyo H; Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona, Spain.
  • Alfon J; Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona, Spain.
  • Yeste-Velasco M; Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona, Spain.
  • Santacana M; Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, Lleida, Spain.
  • Dolcet X; Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, Lleida, Spain.
  • Reques A; Pathology Department, Vall Hebron University Hospital, Barcelona, Spain.
  • Oaknin A; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Rodríguez-Freixinos V; Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Lizcano JM; Protein Kinases and Signal Transduction Laboratory, Institut de Neurociències and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain.
  • Domènech C; Ability Pharmaceuticals, SL, Cerdanyola Del Vallès, Barcelona, Spain.
  • Gil-Moreno A; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain; Gynecological Oncology Department, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain. Electronic address: agil@vhebron.net.
  • Matias-Guiu X; Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, Lleida, Spain; Department of Pathology, University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de
  • Colas E; Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain. Electronic address: eva.colas@vhir.org.
  • Eritja N; Department of Pathology and Molecular Genetics/Oncologic Pathology Group, Biomedical Research Institute of Lleida (IRBLleida), University of Lleida, CIBERONC, Lleida, Spain. Electronic address: neritja@irblleida.cat.
Gynecol Oncol ; 153(2): 425-435, 2019 05.
Article em En | MEDLINE | ID: mdl-30853360
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Repressoras / Neoplasias do Endométrio / Proteínas Serina-Treonina Quinases / Proteínas de Ciclo Celular / Bibliotecas de Moléculas Pequenas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Aged / Animals / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Repressoras / Neoplasias do Endométrio / Proteínas Serina-Treonina Quinases / Proteínas de Ciclo Celular / Bibliotecas de Moléculas Pequenas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Aged / Animals / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha